Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels

G. Robustelli Della Cuna, F. Pannuti, A. Martoni, C. M. Camaggi, E. Strocchi, G. A. Da Prada, S. Tanneberger

Research output: Contribution to journalArticle

Abstract

In a multicenter randomized clinical trial 106 postmenopausal patients with progressive metastatic breast cancer were allocated to receive 500 mg or 1000 mg Aminoglutethimide (AG) per os daily. Cortisone Acetate (CA) replacement dose was 37.5 mg/day orally in both groups. In 91 fully evaluable patients no statistically significant difference was observed between the two therapeutic regimens neither in terms of overall response (28 vs 35%) and by site responses nor in terms of median time to progression (10.5 vs 14.5 months) and media)l overall survival (20 vs. 22 months). The tolerability was satisfactory in both regimens. Although no statistically significant differences occurred in the low dose regimen we observed fewer patients with side-effects (25% vs 6%) and induced grade 3 side-effects (4% vs 9%). Our results confirm that AG daily doses of 500 and 1000 mg associated with corticosteroids have a comparable effect. Because of its slight but clinically noticeable better tolerability, the lower dose is the preferable regimen in the treatment of advanced breast cancer.

Original languageEnglish
Pages (from-to)2367-2371
Number of pages5
JournalAnticancer Research
Volume13
Issue number6 B
Publication statusPublished - 1993

Fingerprint

Aminoglutethimide
Breast Neoplasms
Adrenal Cortex Hormones
Randomized Controlled Trials
Survival
Therapeutics

Keywords

  • Aminoglutethimide
  • Metastatic breast cancer
  • Optimal daily dose
  • Randomized study

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Robustelli Della Cuna, G., Pannuti, F., Martoni, A., Camaggi, C. M., Strocchi, E., Da Prada, G. A., & Tanneberger, S. (1993). Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels. Anticancer Research, 13(6 B), 2367-2371.

Aminoglutethimide in advanced breast cancer : Prospective, randomized comparison of two dose levels. / Robustelli Della Cuna, G.; Pannuti, F.; Martoni, A.; Camaggi, C. M.; Strocchi, E.; Da Prada, G. A.; Tanneberger, S.

In: Anticancer Research, Vol. 13, No. 6 B, 1993, p. 2367-2371.

Research output: Contribution to journalArticle

Robustelli Della Cuna, G, Pannuti, F, Martoni, A, Camaggi, CM, Strocchi, E, Da Prada, GA & Tanneberger, S 1993, 'Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels', Anticancer Research, vol. 13, no. 6 B, pp. 2367-2371.
Robustelli Della Cuna G, Pannuti F, Martoni A, Camaggi CM, Strocchi E, Da Prada GA et al. Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels. Anticancer Research. 1993;13(6 B):2367-2371.
Robustelli Della Cuna, G. ; Pannuti, F. ; Martoni, A. ; Camaggi, C. M. ; Strocchi, E. ; Da Prada, G. A. ; Tanneberger, S. / Aminoglutethimide in advanced breast cancer : Prospective, randomized comparison of two dose levels. In: Anticancer Research. 1993 ; Vol. 13, No. 6 B. pp. 2367-2371.
@article{f8114043cd214350bc0498f302e31352,
title = "Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels",
abstract = "In a multicenter randomized clinical trial 106 postmenopausal patients with progressive metastatic breast cancer were allocated to receive 500 mg or 1000 mg Aminoglutethimide (AG) per os daily. Cortisone Acetate (CA) replacement dose was 37.5 mg/day orally in both groups. In 91 fully evaluable patients no statistically significant difference was observed between the two therapeutic regimens neither in terms of overall response (28 vs 35{\%}) and by site responses nor in terms of median time to progression (10.5 vs 14.5 months) and media)l overall survival (20 vs. 22 months). The tolerability was satisfactory in both regimens. Although no statistically significant differences occurred in the low dose regimen we observed fewer patients with side-effects (25{\%} vs 6{\%}) and induced grade 3 side-effects (4{\%} vs 9{\%}). Our results confirm that AG daily doses of 500 and 1000 mg associated with corticosteroids have a comparable effect. Because of its slight but clinically noticeable better tolerability, the lower dose is the preferable regimen in the treatment of advanced breast cancer.",
keywords = "Aminoglutethimide, Metastatic breast cancer, Optimal daily dose, Randomized study",
author = "{Robustelli Della Cuna}, G. and F. Pannuti and A. Martoni and Camaggi, {C. M.} and E. Strocchi and {Da Prada}, {G. A.} and S. Tanneberger",
year = "1993",
language = "English",
volume = "13",
pages = "2367--2371",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Aminoglutethimide in advanced breast cancer

T2 - Prospective, randomized comparison of two dose levels

AU - Robustelli Della Cuna, G.

AU - Pannuti, F.

AU - Martoni, A.

AU - Camaggi, C. M.

AU - Strocchi, E.

AU - Da Prada, G. A.

AU - Tanneberger, S.

PY - 1993

Y1 - 1993

N2 - In a multicenter randomized clinical trial 106 postmenopausal patients with progressive metastatic breast cancer were allocated to receive 500 mg or 1000 mg Aminoglutethimide (AG) per os daily. Cortisone Acetate (CA) replacement dose was 37.5 mg/day orally in both groups. In 91 fully evaluable patients no statistically significant difference was observed between the two therapeutic regimens neither in terms of overall response (28 vs 35%) and by site responses nor in terms of median time to progression (10.5 vs 14.5 months) and media)l overall survival (20 vs. 22 months). The tolerability was satisfactory in both regimens. Although no statistically significant differences occurred in the low dose regimen we observed fewer patients with side-effects (25% vs 6%) and induced grade 3 side-effects (4% vs 9%). Our results confirm that AG daily doses of 500 and 1000 mg associated with corticosteroids have a comparable effect. Because of its slight but clinically noticeable better tolerability, the lower dose is the preferable regimen in the treatment of advanced breast cancer.

AB - In a multicenter randomized clinical trial 106 postmenopausal patients with progressive metastatic breast cancer were allocated to receive 500 mg or 1000 mg Aminoglutethimide (AG) per os daily. Cortisone Acetate (CA) replacement dose was 37.5 mg/day orally in both groups. In 91 fully evaluable patients no statistically significant difference was observed between the two therapeutic regimens neither in terms of overall response (28 vs 35%) and by site responses nor in terms of median time to progression (10.5 vs 14.5 months) and media)l overall survival (20 vs. 22 months). The tolerability was satisfactory in both regimens. Although no statistically significant differences occurred in the low dose regimen we observed fewer patients with side-effects (25% vs 6%) and induced grade 3 side-effects (4% vs 9%). Our results confirm that AG daily doses of 500 and 1000 mg associated with corticosteroids have a comparable effect. Because of its slight but clinically noticeable better tolerability, the lower dose is the preferable regimen in the treatment of advanced breast cancer.

KW - Aminoglutethimide

KW - Metastatic breast cancer

KW - Optimal daily dose

KW - Randomized study

UR - http://www.scopus.com/inward/record.url?scp=0027881621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027881621&partnerID=8YFLogxK

M3 - Article

C2 - 8135469

AN - SCOPUS:0027881621

VL - 13

SP - 2367

EP - 2371

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -